Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The p53 tumor suppressor is a potent transcription factor that plays a key role in the regulation of cellular responses to stress. It is controlled by its negative regulator MDM2, which binds directly to p53 and inhibits its transcriptional activity. MDM2 also targets p53 for degradation by the proteasome. Many tumors produce high levels of MDM2, thereby impairing p53 function. Restoration of p53 activity by inhibiting the p53-MDM2 interaction may represent a novel approach to cancer treatment. RG7112 (2g) is the first clinical small-molecule MDM2 inhibitor designed to occupy the p53-binding pocket of MDM2. In cancer cells expressing wild-type p53, RG7112 stabilizes p53 and activates the p53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“By binding to MDM2, RG-7112 inhibits the interaction between p53 and MDM2, preventing the degradation of the p53 proteasome, which leads to stabilization and increased levels of the tumor suppressor protein p53 in the cell.369”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [369]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“MDM4 amplification was even shown to reduce sensitivity of cells to Nutlin-3 [29–31].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“WB138 increases the levels of both p53 and MDM2, which is consistent with the activity of previous reports on MDM2 inhibitors[28,32–36].”
From Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries (2021) · cites this paper as [35]
In the citing paper
“RG7112 was modified by Roche based on the structure of Nutlins and was the first to be introduced into clinical trials (Fig. 4) [19].”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [19]
In the citing paper
“The crystal structure showed that the 4-chlorophenyl ring occupied the Trp23 and Leu26 pockets, while the ethoxy group was prominently located in the Phe19 pocket341 (Fig. 8d).”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [341]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Self-citationRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Self-citation
Research works printed but not linked: 2
- Iwakuma T., 2003, Mol. Cancer Res., 1, 993
- Vu B. T., 2011, Curr. Top. Microbiol. Immunol., 348, 151
Cited by
Items 401–453 of 453
Role of MDM2 in Hypertrophic Cardiomyopathy
Shridhar, P. (2023) · D-Scholarship@Pitt (University of Pittsburgh)
studi rivolti alla sintesi di (-)-nutlin-3
Cristofori, V. (2015) · Electronic Theses and Dissertations Repository (University of Pisa)
Lam, B. (2019) · YorkSpace (York University)
Spinal senescence as a therapeutic target to treat painful disc degeneration
Sagir, J. (2025) · eScholarship@McGill (McGill) · doi:10.82308/5851
Chua, A. J. K., Francesco, V. D., Tesar, B. M., Cathcart, A. M., Bird, G. H., Godes, M., Medha, M. M., Kim, J., Wu, R., Filbin, M. G., et al. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0748
Protein-protein interaction inhibitors in cancer
Hardcastle, I. R., Goujon-Ricci, J., & Thompson, W. I. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00067-4
Al‐Zoubi, R. M., Elaarag, M., Zarour, A. A., Garada, K., Al-Zoubi, S. R., Fares, Z. E., Al-Qudimat, A. R., Shkoor, M., Khan, A., Sawali, M. A., et al. (2026) · Drug Development Research · doi:10.1002/ddr.70246 · Cited by 1
タンパク質間相互作用阻害活性を有するThielocin B1の全合成およびその作用機構解明に向けた研究
大澤, 宏. (2015) · Institutional Repositories DataBase (IRDB)
L'oncogène Mdm2 : nouvelles fonctions et implications dans le métabolisme des cellules cancéreuses
Riscal, R. (2016) · theses.fr (ABES) · doi:10.70675/8323431fzb45az4c76z9dabza616829d50ef
Glioblastoma resistance to temozolomide : implication of α5β1 integrin and p53 signalling pathways
Sani, S. (2020) · theses.fr (ABES) · doi:10.70675/9566c585z0508z455bz9064z6bb61435b210
Analyse du rôle des protéines FAK et CD47 dans l'invasion tumorale du mélanome
Mousson, A. (2020) · theses.fr (ABES) · doi:10.70675/fe000e00ze698z4536za6b1z7b9986716e1f
Yeni 1,4-oksazepan-5-on ve kumarin türevlerinin sentezine yönelik çalışmalar
Akbas, T. (2022) · IYTE GCRIS Database (Izmir Institute of Technology)
A yeast-based assay to screen protein-protein interaction modulators
Sudevan, A. (2021) · theses.fr (ABES) · doi:10.70675/9ab04dcaz498fz43ebz8762z012f3f86154c
Chédeville, A. L. (2024) · theses.fr (ABES) · doi:10.70675/aedc1abbzfc5az467czb2e6z257318a9eaba
DNA‐Encoded Libraries for the Discovery of E3 Ligase Ligands
Wen, L., Zhang, Q., Duan, Z., Jin, R., & Lu, X. (2026) · ChemMedChem · doi:10.1002/cmdc.202501032
Hamburger, E. C. B., Darband, S. G., Cardahi, F., Ouellet, J. A., Weber, M. H., Garzia, L., Haglund, L., & Rosenzweig, D. H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.12.724653
Zhang, M., Hu, C., Liu, H., Zhang, C., Shu, Q., Kang, Y.-J., Ding, Y., Zhang, J., Hu, Z., Wang, H., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03824-7
Navigating the p53‐MDM2 Landscape: Molecular Insights and Therapeutic Strategies
Mansour, M. A., Hassan, G. S., & Abouzid, K. A. M. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70264
- Self-citation
Zhao, M., Gao, W., Xia, X., Xia, X., & Qian, Z. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00580
Sackitey, S., Biniyam, P. D., Mireku, C. L., Hammah, A., Buabeng, J. A., Nkrumah, L. K., Asare, W. M., Oppong, J. F., Obeng, E. G., Adu-Adjei, K., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10832690/v1
Centomo, M. L. (2023) · Institutional Research Information System University of Turin (University of Turin)
GÜNGÖRDÜ, Ş. (2025) · Bilecik Şeyh Edebali University Institutional Repository
Strategies for Overcoming Acquired Resistance of Tumor Cells to MDM2 Inhibitors
Pervushin, N. V., Просандеева, Е. С., Zhivotovsky, B., & Kopeina, G. S. (2026) · Biochemistry (Moscow) · doi:10.1134/s0006297926601875
BindingDB Entry 50010808: Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases.
BindingDB (2021) · UC San Diego · doi:10.7270/q2qn6bbk
BindingDB Entry 50014764: Discovery of
BindingDB (2023) · UC San Diego · doi:10.7270/q2z03d1v
BindingDB (2019) · UC San Diego · doi:10.7270/q25q4zcf
BindingDB Entry 50009301: Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry.
BindingDB (2021) · UC San Diego · doi:10.7270/q2qn6b6s
BindingDB Entry 50007847: Development of selective small molecule MDM2 degraders based on nutlin.
BindingDB (2021) · UC San Diego · doi:10.7270/q22j6g6h
BindingDB (2025) · UC San Diego · doi:10.7270/q2wq08f2
BindingDB (2015) · UC San Diego · doi:10.7270/q2rj4m1c
BindingDB (2019) · UC San Diego · doi:10.7270/q2jw8h51
Development of novel modulators of protein-protein interactions associated with cancer
Healy, A. R. (2014) · St Andrews Research Repository (St Andrews Research Repository)
Investigating the roles of p63 and p73 isoforms to therapeutically treat p53-altered cancers
Venkatanarayan, A. (2015) · Digital Commons-TMC (Texas Medical Center)
Metadata
- Authors
- Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., Tovar, C., Packman, K., Vassilev, L., & Graves, B.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- Discovery Chemistry, ‡Discovery Oncology, §Discovery Technologies, ∥Non-Clinical Development, Roche Research Center, Hoffmann-La Roche, Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
- Corresponding author
- Vu, Binh
- ORCID
- Venue
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-04-04
- Volume
- 4
- Issue
- 5
- Pages
- 466-469
- ISSN
- 1948-5875 (ISSN-L)
- PMC
- PMC4027145
- OpenAlex
- W1985567682
- Cited by
- 395
- References
- 24
- Citations by year
- 2026: 22 · 2025: 42 · 2024: 28 · 2023: 39 · 2022: 39 · 2021: 36 · 2020: 39 · 2019: 39 · 2018: 19 · 2017: 19 · 2016: 16 · 2015: 28 · 2014: 20 · 2013: 8
- FWCI
- 13.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- ACS Medicinal Chemistry Letters (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- RG7112, MDM2 inhibitors, p53, p53-MDM2 interaction, small molecule drug discovery, p53 stabilization, cancer therapy, cell cycle arrest, apoptosis, tumor xenografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.